Corticotropin
Acthar, Cortrophin (corticotropin) is a protein pharmaceutical. Corticotropin was first approved as Purified cortrophin gel on 1982-01-01. It is used to treat collagen diseases, erythema multiforme, infantile spasms, multiple sclerosis, and nephrotic syndrome amongst others in the USA. The pharmaceutical is active against adrenocorticotropic hormone receptor. In addition, it is known to target CRHR1-IT1-CRHR1 protein, melanocortin receptor 5, melanocortin receptor 4, melanocyte-stimulating hormone receptor, melanocortin receptor 3, and corticotropin-releasing factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Acthar, Cortrophin (discontinued: Acth)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Corticotropin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PURIFIED CORTROPHIN GEL | ANI PHARMS | N-008975 RX | 1982-01-01 | 1 products, RLD, RS |
| ACTHAR GEL | Mallinckrodt | N-008372 RX | 1982-01-01 | 1 products, RLD, RS |
Show 5 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acthar | New Drug Application | 2023-10-11 |
| acthrel | Biologic Licensing Application | 2021-11-12 |
| h.p. acthar | New Drug Application | 2018-05-09 |
| purified cortrophin gel | New Drug Application | 2023-10-25 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Corticotropin, Acthar Gel, Mallinckrodt Ard | |||
| 11752199 | 2041-02-25 | U-3686, U-3687, U-3688 | |
HCPCS
Code | Description |
|---|---|
| J0800 | Injection, corticotropin, up to 40 units |
Clinical
Clinical Trials
226 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 2 | 2 | 5 | 2 | 11 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | 1 | 5 | 2 | 9 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 2 | 2 | 3 | 2 | 7 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | 2 | 4 | 7 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | 1 | 3 | 2 | 6 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | 1 | 1 | 1 | 2 | — | 5 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | 1 | 3 | 1 | 5 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | — | — | 4 | — | 4 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | — | 1 | 2 | 4 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | 1 | 2 | 4 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | 5 | 6 | — | 5 | 16 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 2 | 3 | — | — | 5 |
| Brain edema | D001929 | EFO_1000845 | G93.6 | 1 | 2 | 3 | — | — | 5 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | 2 | — | 1 | 3 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 2 | 1 | — | — | 2 |
| Psychological sexual dysfunctions | D020018 | — | F52.0 | — | — | 2 | — | — | 2 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | 1 | — | 1 | 2 |
| Hypercalcemia | D006934 | HP_0003072 | E83.52 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | 2 | 4 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | 1 | — | — | 2 | 4 |
| Pituitary neoplasms | D010911 | — | — | 1 | 1 | — | — | 1 | 3 |
| Polymyositis | D017285 | EFO_0003063 | M33.2 | — | 1 | — | — | 2 | 3 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 2 | — | — | 1 | 3 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | 1 | 1 | — | — | 1 | 2 |
| Infantile spasms | D013036 | HP_0011097 | G40.82 | — | 1 | — | — | 1 | 2 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | 1 | 1 | — | — | — | 2 |
| Alcohol-related disorders | D019973 | — | F10 | — | 1 | — | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | D000309 | — | — | 2 | — | — | — | 6 | 8 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | 1 | 2 |
| Adrenal cortex diseases | D000303 | — | — | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Cannabis | D002188 | — | — | 1 | — | — | — | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | 1 | — | — | — | — | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | — | — | — | — | 1 |
| Proliferative vitreoretinopathy | D018630 | EFO_1001129 | — | 1 | — | — | — | — | 1 |
| Optic neuritis | D009902 | EFO_0007405 | H46 | 1 | — | — | — | — | 1 |
| Edema | D004487 | HP_0000969 | R60.9 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 3 | 3 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | — | — | — | 2 | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 2 | 2 |
| Cataract | D002386 | HP_0000518 | H26.9 | — | — | — | — | 2 | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
| Neck pain | D019547 | HP_0030833 | M54.2 | — | — | — | — | 1 | 1 |
| Back pain | D001416 | HP_0003418 | M54 | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 1 | 1 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | — | — | 1 | 1 |
Show 42 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Corticotropin |
| INN | corticotropin |
| Description | Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland comprising 39 amino acid residues coupled in a linear sequence. The N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). It is used in the treatment of certain neurological disorders such as infantile spasms and multiple sclerosis, and diagnostically to investigate adrenocortical insufficiency. It has a role as a diagnostic agent. It is a polypeptide, a peptide hormone and a biomacromolecule. |
| Classification | Protein |
| Drug class | atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9002-60-2 |
| RxCUI | 376 |
| ChEMBL ID | CHEMBL1201610 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01285 |
| UNII ID | K0U68Q2TXA (ChemIDplus, GSRS) |
Target
Agency Approved
MC2R
MC2R
Organism
Homo sapiens
Gene name
MC2R
Gene synonyms
ACTHR
NCBI Gene ID
Protein name
adrenocorticotropic hormone receptor
Protein synonyms
ACTH receptor, Adrenocorticotropin receptor, corticotropin receptor, MC2 receptor, MC2-R, melanocortin 2 receptor (adrenocorticotropic hormone), Melanocortin receptor 2
Uniprot ID
Mouse ortholog
Mc2r (17200)
adrenocorticotropic hormone receptor (Q64326)
Alternate
LINC02210-CRHR1
LINC02210-CRHR1
MC5R
MC5R
MC4R
MC4R
MC1R
MC1R
MC3R
MC3R
CRHR2
CRHR2
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Corticotropin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 85,233 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,302 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use